Northern Trust’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-149,035
| Closed | -$340K | – | 4465 |
|
|
2024
Q2 | $340K | Buy |
149,035
+23,522
| +19% | +$89.8K | ﹤0.01% | 3651 |
|
|
2024
Q1 | $542K | Sell |
125,513
-11
| -0% | -$38 | ﹤0.01% | 3537 |
|
|
2023
Q4 | $383K | Buy |
125,524
+26,180
| +26% | +$49.2K | ﹤0.01% | 3634 |
|
|
2023
Q3 | $143K | Sell |
99,344
-369
| -0.4% | -$714 | ﹤0.01% | 3921 |
|
|
2023
Q2 | $248K | Sell |
99,713
-24,836
| -20% | -$67.8K | ﹤0.01% | 3741 |
|
|
2023
Q1 | $334K | Buy |
124,549
+6,792
| +6% | +$32.6K | ﹤0.01% | 3617 |
|
|
2022
Q4 | $639K | Buy |
117,757
+24,782
| +27% | +$208K | ﹤0.01% | 3417 |
|
|
2022
Q3 | $1.16M | Buy |
92,975
+1,084
| +1% | +$12.4K | ﹤0.01% | 3265 |
|
|
2022
Q2 | $454K | Sell |
91,891
-298,695
| -76% | -$1.65M | ﹤0.01% | 3569 |
|
|
2022
Q1 | $2.97M | Sell |
390,586
-16,381
| -4% | -$155K | ﹤0.01% | 2887 |
|
|
2021
Q4 | $4.16M | Buy |
406,967
+1,056
| +0.3% | +$13.5K | ﹤0.01% | 2804 |
|
|
2021
Q3 | $5.45M | Sell |
405,911
-14,461
| -3% | -$236K | ﹤0.01% | 2675 |
|
|
2021
Q2 | $9.22M | Buy |
420,372
+44,685
| +12% | +$993K | ﹤0.01% | 2429 |
|
|
2021
Q1 | $9.04M | Sell |
375,687
-24,326
| -6% | -$565K | ﹤0.01% | 2359 |
|
|
2020
Q4 | $7.2M | Sell |
400,013
-15,930
| -4% | -$238K | ﹤0.01% | 2457 |
|
|
2020
Q3 | $4.8M | Sell |
415,943
-15,862
| -4% | -$262K | ﹤0.01% | 2554 |
|
|
2020
Q2 | $10.5M | Buy |
431,805
+13,311
| +3% | +$220K | ﹤0.01% | 2061 |
|
|
2020
Q1 | $4.61M | Sell |
418,494
-1,369
| -0.3% | -$25.6K | ﹤0.01% | 2350 |
|
|
2019
Q4 | $11.1M | Buy |
419,863
+15,853
| +4% | +$371K | ﹤0.01% | 2109 |
|
|
2019
Q3 | $9.2M | Buy |
404,010
+101,558
| +34% | +$3.2M | ﹤0.01% | 2197 |
|
|
2019
Q2 | $9.27M | Buy |
302,452
+12,300
| +4% | +$259K | ﹤0.01% | 2198 |
|
|
2019
Q1 | $4.82M | Buy |
290,152
+8,472
| +3% | +$161K | ﹤0.01% | 2586 |
|
|
2018
Q4 | $5.39M | Buy |
281,680
+19,360
| +7% | +$725K | ﹤0.01% | 2460 |
|
|
2018
Q3 | $13.7M | Buy |
262,320
+19,825
| +8% | +$1.08M | ﹤0.01% | 2061 |
|
|
2018
Q2 | $10.5M | Buy |
242,495
+86,058
| +55% | +$3.69M | ﹤0.01% | 2234 |
|
|
2018
Q1 | $5.8M | Buy |
156,437
+73,149
| +88% | +$1.95M | ﹤0.01% | 2502 |
|
|
2017
Q4 | $1.65M | Buy |
83,288
+18,239
| +28% | +$392K | ﹤0.01% | 3231 |
|
|
2017
Q3 | $1.62M | Buy |
+65,049
| New | +$1.2M | ﹤0.01% | 3293 |
|
Northern Trust's GTHX Position: Q3 2024 in Review
Northern Trust sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 149,035 shares — an estimated $340K sold.
Northern Trust first reported a position in GTHX in Q3 2017 and held it in 28 quarters. The position peaked at $13.7M in Q3 2018. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Northern Trust reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Northern Trust sold 149,035 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $340K.
- Northern Trust first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2017 and held it in 28 quarters.
- Northern Trust's G1 Therapeutics, Inc. Common Stock position peaked at $13.7M in Q3 2018.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Northern Trust's 13F filing for Q3 2024, filed 13 Nov 2024.